NCT06426134View on ClinicalTrials.gov

Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Schizophrenia and Related DisordersPsychosisBipolar and Related DisordersManic EpisodeDepressive Episode
Interventions
DIETARY_SUPPLEMENT

(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)

1x50g ingestion of pure dGK

OTHER

Maltodextrin, Fructose, Pectin, Sodium alginate, Sodium chloride

Isocaloric carbohydrate control (active control)

Trial Locations (1)

1105 AZ

RECRUITING

Amsterdam UMC, dept. Psychiatry, Amsterdam

Sponsors

Collaborators (1)

EnLiSense
All Listed Sponsors
collaborator

Parnassia Groep

OTHER

collaborator

The University of Texas at Dallas

OTHER

collaborator

University of Alberta

OTHER

collaborator

EnLiSense

UNKNOWN

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT06426134 - Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS | Biotech Hunter | Biotech Hunter